<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02899156</url>
  </required_header>
  <id_info>
    <org_study_id>837421</org_study_id>
    <nct_id>NCT02899156</nct_id>
  </id_info>
  <brief_title>Flumazenil for Hypoactive Delirium Secondary to Benzodiazepine Toxicity</brief_title>
  <acronym>FLYP</acronym>
  <official_title>Effect of Flumazenil on Hypoactive Delirium Secondary to Benzodiazepine Toxicity in the ICU</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Davis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, Davis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Delirium within the intensive care unit (ICU) is associated with poor outcomes such as
      increased mortality, ICU and hospital length of stay (LOS), and time on mechanical
      ventilation. Benzodiazepine (BZD) exposure is an independent risk factor for development of
      delirium. Reversal of hypoactive delirium represents a potential opportunity for reducing
      duration of delirium and subsequent complications.

      This is a single-center randomized, double-blind, placebo-controlled study of critically ill
      adult patients with benzodiazepine-associated hypoactive delirium. The hypothesis is that
      flumazenil continuous infusion reverses hypoactive delirium associated with BZD toxicity and
      thereby reduces duration of delirium and ICU LOS.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Benzodiazepines are commonly used for discomfort, anxiety, agitation, and alcohol withdrawal
      syndrome (AWS) in the ICU. End organ dysfunction and extended exposure can increase the risk
      of complications associated with BZDs, which include increased ICU LOS, time on mechanical
      ventilation, and mortality.

      Flumazenil as a 1, 4-imidazobenzodiazepine is a competitive antagonist for the benzodiazepine
      binding site with weak intrinsic or partial agonistic activity on the GABA receptor. Multiple
      studies have confirmed the safety and effectiveness of flumazenil for the reversal of
      sedation. Pilot studies have demonstrated safe reversal of over-sedation and statistically
      significant improvements in patient cooperation and time to extubation. The current standard
      for suspected BZD-associated hypoactive delirium is cessation of benzodiazepine
      administration and supportive care.

      The role of continuous infusion flumazenil for rapid and sustained reversal of hypoactive
      delirium in the ICU has not been evaluated prospectively and therefore remains poorly
      defined.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Anticipated">May 2019</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>number of delirium-free days</measure>
    <time_frame>up to 14 days after randomization</time_frame>
    <description>defined by the number of days in the 14-day period after randomization that the patient was alive and not delirious (i.e. CAM-ICU negative). Zero delirium-free days will be observed for patients that die within the 14-day period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>length of ICU stay defined as the time between randomization and ICU transfer orders</measure>
    <time_frame>up to 28 days after randomization</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>occurrence of agitation while on study infusion</measure>
    <time_frame>up to 72 hours after the start of the infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>occurrence of seizure while on study infusion</measure>
    <time_frame>up to 72 hours after the start of the infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>occurrence of supra ventricular arrhythmia while on study infusion</measure>
    <time_frame>up to 72 hours after the start of the infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>occurrence of agitation requiring use of rescue sedatives while on study infusion</measure>
    <time_frame>up to 72 hours after the start of the infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hospital length of stay</measure>
    <time_frame>up to 28 days after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>average duration of study infusion</measure>
    <time_frame>up to 72 hours after the start of the infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>average dose of study infusion</measure>
    <time_frame>up to 72 hours after the start of the infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of ventilator-free days</measure>
    <time_frame>up to 28 days after randomization</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Delirium</condition>
  <arm_group>
    <arm_group_label>Flumazenil Infusion</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The flumazenil continuous infusion is started at an initial dose of 0.1 mg/hr., and can be titrated up to a maximum of 0.3 mg/hr. Dose titrations may occur every 60 minutes to maintain RASS scores of 0 to +1. The maximum rate is 0.3 mg/hr.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Infusion</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The placebo continuous infusion is started at an initial dose of 0.1 mg/hr., and can be titrated up to a maximum of 0.3 mg/hr. Dose titrations may occur every 60 minutes to maintain RASS scores of 0 to +1. The maximum rate is 0.3 mg/hr.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Flumazenil</intervention_name>
    <arm_group_label>Flumazenil Infusion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>0.9% normal saline</description>
    <arm_group_label>Placebo Infusion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  critically ill adults

          -  RASS score of -3 to +1

          -  CAM-ICU positive

          -  no benzodiazepine therapy within the previous 12 hours

        Exclusion Criteria:

          -  Contraindications to flumazenil including hypersensitivity and receipt of
             benzodiazepines for control of potentially life-threatening conditions (eg, control of
             intracranial pressure or status epilepticus)

          -  active seizure disorder or on current anti-convulsant therapy for history of seizure
             disorder. Seizures secondary to alcohol withdrawal will NOT be excluded

          -  history of traumatic brain injury complicated by seizures

          -  acute episode (within prior 30 days) of severe traumatic brain injury

          -  history of structural lesion (e.g. subarachnoid hemorrhage, cerebrovascular accident,
             intra-parenchymal hemorrhage) complicated by seizures

          -  acute episode (within prior 14 days) of structural lesion (e.g. subarachnoid
             hemorrhage, cerebrovascular accident, intra-parenchymal hemorrhage)

          -  brain tumor complicated by seizure

          -  history of anoxic brain injury

          -  third-degree burn with total body surface area (TBSA) burn greater than 20%

          -  chronic benzodiazepine (clonazepam:lorazepam:diazepam approximately 4:8:40 mg per day)
             for 7 consecutive days with no taper

          -  history of chronic delirium that is attributable to other causes

          -  anticipated to transfer to lower level of care within 24 hours

          -  admitted for polysubstance overdose (as determined by initial drug toxicity screening)

          -  recent exposure (prior 7 days) to pro-convulsant medications (identified via
             medication history or available urine drug screening) i.e. tricyclic antidepressants,
             bupropion

          -  children, incarcerated individuals, and pregnant women

          -  unable to provide consent and the legally authorized representative is unable to
             provide consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kendra J Schomer, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Davis</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jeremiah J Duby, PharmD, BCPS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Davis</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kendra J Schomer, PharmD</last_name>
    <phone>916-734-2243</phone>
    <email>kjschomer@ucdavis.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jeremiah J Duby, PharmD, BCPS</last_name>
    <phone>916-734-3923</phone>
    <email>jjduby@ucdavis.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UC Davis Medical Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kendra J Schomer, PharmD</last_name>
      <phone>916-734-2243</phone>
      <email>kjschomer@ucdavis.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jeremiah J Duby, PharmD, BCPS</last_name>
      <phone>916-734-3923</phone>
      <email>jjduby@ucdavis.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Kendra Schomer, PharmD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jeremiah Duby, PharmD, BCPS</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Erin Louie, PharmD, BCPS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christine Cocanour, MD, FACS, FCCM</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christian Sebat, DO</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Peter Trovitch, PharmD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rachelle Firestone, PharmD, BCPS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dawn Love, RN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Timothy Albertson, MD, MPH, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Pandharipande P, Shintani A, Peterson J, Pun BT, Wilkinson GR, Dittus RS, Bernard GR, Ely EW. Lorazepam is an independent risk factor for transitioning to delirium in intensive care unit patients. Anesthesiology. 2006 Jan;104(1):21-6.</citation>
    <PMID>16394685</PMID>
  </reference>
  <reference>
    <citation>Zaal IJ, Devlin JW, Hazelbag M, Klein Klouwenberg PM, van der Kooi AW, Ong DS, Cremer OL, Groenwold RH, Slooter AJ. Benzodiazepine-associated delirium in critically ill adults. Intensive Care Med. 2015 Dec;41(12):2130-7. doi: 10.1007/s00134-015-4063-z. Epub 2015 Sep 24.</citation>
    <PMID>26404392</PMID>
  </reference>
  <reference>
    <citation>Shehabi Y, Bellomo R, Reade MC, Bailey M, Bass F, Howe B, McArthur C, Seppelt IM, Webb S, Weisbrodt L; Sedation Practice in Intensive Care Evaluation (SPICE) Study Investigators; ANZICS Clinical Trials Group. Early intensive care sedation predicts long-term mortality in ventilated critically ill patients. Am J Respir Crit Care Med. 2012 Oct 15;186(8):724-31. doi: 10.1164/rccm.201203-0522OC. Epub 2012 Aug 2.</citation>
    <PMID>22859526</PMID>
  </reference>
  <reference>
    <citation>Ely EW, Shintani A, Truman B, Speroff T, Gordon SM, Harrell FE Jr, Inouye SK, Bernard GR, Dittus RS. Delirium as a predictor of mortality in mechanically ventilated patients in the intensive care unit. JAMA. 2004 Apr 14;291(14):1753-62.</citation>
    <PMID>15082703</PMID>
  </reference>
  <reference>
    <citation>Patel SB, Poston JT, Pohlman A, Hall JB, Kress JP. Rapidly reversible, sedation-related delirium versus persistent delirium in the intensive care unit. Am J Respir Crit Care Med. 2014 Mar 15;189(6):658-65. doi: 10.1164/rccm.201310-1815OC.</citation>
    <PMID>24423152</PMID>
  </reference>
  <reference>
    <citation>Brogden RN, Goa KL. Flumazenil. A reappraisal of its pharmacological properties and therapeutic efficacy as a benzodiazepine antagonist. Drugs. 1991 Dec;42(6):1061-89. Review. Erratum in: Drugs 1992 Apr;43(4):442.</citation>
    <PMID>1724638</PMID>
  </reference>
  <reference>
    <citation>Breheny FX. Reversal of midazolam sedation with flumazenil. Crit Care Med. 1992 Jun;20(6):736-9.</citation>
    <PMID>1597024</PMID>
  </reference>
  <reference>
    <citation>Pepperman ML. Double-blind study of the reversal of midazolam-induced sedation in the intensive care unit with flumazenil (Ro 15-1788): effect on weaning from ventilation. Anaesth Intensive Care. 1990 Feb;18(1):38-44.</citation>
    <PMID>2110788</PMID>
  </reference>
  <reference>
    <citation>Penninga EI, Graudal N, Ladekarl MB, Jürgens G. Adverse Events Associated with Flumazenil Treatment for the Management of Suspected Benzodiazepine Intoxication--A Systematic Review with Meta-Analyses of Randomised Trials. Basic Clin Pharmacol Toxicol. 2016 Jan;118(1):37-44. doi: 10.1111/bcpt.12434. Epub 2015 Jul 28. Review.</citation>
    <PMID>26096314</PMID>
  </reference>
  <reference>
    <citation>Kreshak AA, Cantrell FL, Clark RF, Tomaszewski CA. A poison center's ten-year experience with flumazenil administration to acutely poisoned adults. J Emerg Med. 2012 Oct;43(4):677-82. doi: 10.1016/j.jemermed.2012.01.059. Epub 2012 Jul 4.</citation>
    <PMID>22766408</PMID>
  </reference>
  <reference>
    <citation>Moore PW, Donovan JW, Burkhart KK, Waskin JA, Hieger MA, Adkins AR, Wert Y, Haggerty DA, Rasimas JJ. Safety and efficacy of flumazenil for reversal of iatrogenic benzodiazepine-associated delirium toxicity during treatment of alcohol withdrawal, a retrospective review at one center. J Med Toxicol. 2014 Jun;10(2):126-32. doi: 10.1007/s13181-014-0391-6.</citation>
    <PMID>24619543</PMID>
  </reference>
  <reference>
    <citation>Bodenham A, Park GR. Reversal of prolonged sedation using flumazenil in critically ill patients. Anaesthesia. 1989 Jul;44(7):603-5.</citation>
    <PMID>2505628</PMID>
  </reference>
  <reference>
    <citation>Spivey WH, Roberts JR, Derlet RW. A clinical trial of escalating doses of flumazenil for reversal of suspected benzodiazepine overdose in the emergency department. Ann Emerg Med. 1993 Dec;22(12):1813-21.</citation>
    <PMID>8239101</PMID>
  </reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 27, 2016</study_first_submitted>
  <study_first_submitted_qc>September 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2016</study_first_posted>
  <last_update_submitted>May 24, 2017</last_update_submitted>
  <last_update_submitted_qc>May 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Delirium</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Flumazenil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

